After six weeks of treatment, 83% had little or no cancer remaining at surgery
Agenus' botensilimab and balstilimab combination therapy showed 83% of patients with locally advanced dMMR colon cancer had little or no cancer remaining at surgery. The NEOASIS study met its primary endpoint, with mild side effects reported. Agenus is exploring organ preservation in rectal cancer and advancing the approach in MSS colon cancer. The company aims to reduce treatment duration and chemotherapy use.
How this was made
The 30-second read
Why it matters
The trial results represent a potential breakthrough for short‑course immunotherapy, likely prompting analyst upgrades and increased trading volume.
Market read
First public disclosure of strong Phase 2 data; likely catalyst for Agenus stock and may influence peer biotech valuations.
What to watch
Small cohort size (18 patients) and short follow‑up may temper investor enthusiasm.
Background
Agenus presented neoadjuvant immunotherapy data at the AACR meeting, showing high pathologic response rates in a high‑risk colon cancer cohort.
Ticker impact
Phase 2 trial of botensilimab + balstilimab shows 83% major pathologic response in dMMR colon cancer cohort.
upward pressure as market absorbs strong response rates.
First disclosure of high‑response trial results; biotech stocks typically react sharply to such data.
Market effects
May boost sentiment for immuno‑oncology peers and drive interest in CTLA‑4/PD‑1 combos.
Limited to US biotech sector; no broader regional effect.
Highlights progress in dMMR colorectal cancer therapy, relevant to global oncology pipelines.
Counterpoint
If later‑stage data fail to confirm durability, early hype could reverse.
Key entities
- companyAgenus Inc.
US‑listed immuno‑oncology biotech (NASDAQ: AGEN).
- drugBotensilimab
CTLA‑4 antibody under investigation.
- drugBalstilimab
PD‑1 antibody under investigation.
